Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (18546)	4/3/1998 8:26:00 AM
From: Flagrante Delictu	Read Replies (1) \| Respond to of 32384

Henry, Thanks for the heads up. I looked at the same list with what must have been a dead eye, because the nuances you mentioned, completely eluded me. It looks like we've got the molecules moving toward their manifest destiny.

To: Henry Niman who wrote (18546)	4/3/1998 8:43:00 AM
From: WTDEC	Respond to of 32384

H, there is a lot of good news in the updated pipeline list. Given the large number of drugs under development which are likely to compete with many of ours (the AP article you just posted), LGND needs to continue to move quickly on many fronts. Being first to the market is often more important than having the best product where product differences are great. So, alliances with the big pharmas are obviously crucial (which is why I get upset with GLX apparently is dragging its feet on development) with so many drugs in the pipeline. While difficult and time consuming to develop, a list of competing drugs, current and under development, corresponding to each of LGND's drugs, (along with their respective development status) would be a worthwhile objective. I imagine LGND must have something like that, but I suspect they would consider it proprietary. Regards, W